250 related articles for article (PubMed ID: 24252020)
1. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
2. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.
Fukui S; Nakamura H; Takahashi Y; Iwamoto N; Hasegawa H; Yanagihara K; Nakamura T; Okayama A; Kawakami A
BMC Immunol; 2017 Feb; 18(1):7. PubMed ID: 28158970
[TBL] [Abstract][Full Text] [Related]
5. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study.
Eguchi K; Iwanaga M; Terada K; Aramaki T; Tuji Y; Kurushima S; Kojima K; Arima K; Iwamoto N; Ichinose K; Kawakami A; Hirakata N; Ueki Y
Mod Rheumatol; 2020 May; 30(3):471-480. PubMed ID: 30938551
[No Abstract] [Full Text] [Related]
7. HTLV-1-associated arthropathy treated with anti-TNF-alpha agent.
Frenzel L; Moura B; Marcais A; Chapdelaine H; Hermine O
Joint Bone Spine; 2014 Jul; 81(4):360-1. PubMed ID: 24289962
[TBL] [Abstract][Full Text] [Related]
8. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
9.
Hashiba Y; Umekita K; Minami H; Kawano A; Nagayasu E; Maruyama H; Hidaka T; Okayama A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):16-21. PubMed ID: 32772699
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.
Endo Y; Fukui S; Umekita K; Suzuki T; Miyamoto J; Morimoto S; Shimizu T; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Okada A; Fujikawa K; Mizokami A; Matsuoka N; Aramaki T; Ueki Y; Eguchi K; Kariya Y; Hashiba Y; Hidaka T; Okayama A; Kawakami A; Nakamura H
Mod Rheumatol; 2021 Sep; 31(5):972-978. PubMed ID: 33161771
[TBL] [Abstract][Full Text] [Related]
11. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review.
Liang SJ; Zheng QY; Yang YL; Yang Y; Liu CY
Rheumatol Int; 2017 Jul; 37(7):1207-1212. PubMed ID: 28255643
[TBL] [Abstract][Full Text] [Related]
12. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
13. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J
Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618
[TBL] [Abstract][Full Text] [Related]
14. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
15. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
16. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
17. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
[TBL] [Abstract][Full Text] [Related]
18. HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study.
Umekita K; Hashikura Y; Takaki A; Kimura M; Kawano K; Iwao C; Miyauchi S; Kawaguchi T; Matsuda M; Hashiba Y; Hidaka T
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851682
[TBL] [Abstract][Full Text] [Related]
19. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
